^
Association details:
| Biomarker: | MGMT deletion |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Yervoy (ipilimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O 6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial
Published date:
05/10/2022
Excerpt:
Patients with pretreated mCRC were centrally prescreened for MSS status and MGMT silencing...Eligible patients received two priming cycles of oral temozolomide...combination with ipilimumab...and nivolumab...After a median follow-up of 23.1 months (interquartile range, 14.9-24.6 months), 8-month PFS rate was 36%. Median PFS and overall survival were 7.0 and 18.4 months, respectively, and overall response rate was 45%.
Secondary therapy:
temozolomide
DOI:
10.1200/JCO.21.02583
